NEW YORK -- Japanese drugmaker Takeda Pharmaceutical is aiming to roll out an antibody treatment for COVID-19 as early as this year, as it joins global big pharma's pledge to rise to the occasion amid a global pandemic.
"We believe that within nine to 18 months we could have a product that has real potential to treat the most critically ill patients," Rajeev Venkayya, president of Takeda's global vaccine business unit, said Thursday.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
